characteristics of neurotoxicity associated with ide-cel in pts with rrmm in phase ii karmma
Published 3 years ago • 159 plays • Length 3:41Download video MP4
Download video MP3
Similar videos
-
10:18
ide-cel; bb2121, a bcma-targeted car t-cell therapy, in patients with rrmm: initial karmma results
-
5:16
idecabtagene vicleucel in pts with relapsed and refractory multiple myeloma: updated karmma results
-
9:56
ide-cel vs standard regimens for high-risk multiple myeloma: karmma-3 analysis | asco 2023
-
5:16
updated karmma results: ide-cel in r/r myeloma
-
1:11
toxicities associated with ide-cel in karmma
-
4:34
what is ide-cel and how can it benefit myeloma patients?
-
6:55
karmma2: efficacy and safety of idecabtagene vicleucel in hrmm pts with early relapse after asct
-
1:58
karmma study shows improved qol in patients with r/r multiple myeloma treated with ide-cel
-
14:34
real-world outcomes for patients treated with ide-cel after having received a bcma-targeted therapy
-
8:31
karmma-rw: a study of real-world treatment patterns in heavily pretreated patients with rrmm
-
7:49
idecabtagene vicleucel, a bcma-directed car t cell therapy, in rrmm: updated karmma results
-
9:39
comparing health related quality of life in tce rrmm: ide-cel vs. standard regimens | asco 2023
-
2:19
karmma-4: idecabtagene vicleucel in high-risk newly diagnosed multiple myeloma
-
1:21
factors associated with early progression after ide-cel in patients with r/r multiple myeloma
-
6:34
ide-cel in r/r myeloma: patient-reported outcomes and resistance
-
4:04
ide-cel versus standard regimens in tce r/r multiple myeloma: updated analysis of karmma-3
-
7:55
real-world car-t outcomes, use of ide-cel, cilta-cel for myeloma
-
2:16
updates from the karmma-3 trial: safety profile of ide-cel in tce r/r multiple myeloma
-
0:58
dr. munshi on t-cell persistence with ide-cel in r/r multiple myeloma